Premium
IC‐P‐021: Lower body mass index is associated with greater Alzheimer pathology in asymptomatic individuals
Author(s) -
Gordon Brian Andrew,
Hassenstab Jason,
Fagan Anne M.,
Morris John C.,
Benzinger Tammie L.S.
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.06.041
Subject(s) - body mass index , apolipoprotein e , insulin resistance , pittsburgh compound b , medicine , overweight , obesity , dementia , asymptomatic , pathology , endocrinology , gastroenterology , disease
Pathophysiology (SNAP), a normal or an unclassified group (Table 1). Longitudinal progression to CDR>0 was modeled using survival analyses. Results: Controlling for appropriate covariates, correlations between CSF Ab 42 and the mean cortical PIB binding potential (MCBP) were significant (r1⁄4-.39, p<.0001), while the relationships between adjusted hippocampal volume and CSF (r1⁄4.04, p1⁄4.52) and ptau (r1⁄4.03, p1⁄4.62) were not (Figures 1 & 2). Individuals classified as Stage 2 and 3 were at an elevated risk of later dementia relative to those in Stage 0. (Figures 3-5). Conclusions:The NIA-AA preclinical stages successfully stratify dementia risk using both CSF and neuroimaging biomarkers. Measures of amyloid were highly congruent, while measures of neurodegeneration were often incongruent. This suggests that such markers cannot be used interchangeably to represent the same pathology.